A Prognostic Marker in Idiopathic Sudden Sensorineural Hearing Loss: Serum Calprotectin

İhsan Kuzucu; Tuba Çandar; Deniz Baklacı; İsmail Güler; Rauf Oğuzhan Kum; Hande Arslan; Müge Özcan

추천

검색

자료유형: 학술저널

저자정보: İhsan Kuzucu Tuba Çandar Deniz Baklacı İsmail Güler Rauf Oğuzhan Kum Hande Arslan Müge Özcan

저널정보: 대한이비인후과학회 Clinical and Experimental Otorhinolaryngology Clinical and Experimental Otorhinolaryngology 제13권 제1호

발행연도: 2020.1

수록면: 36 - 40 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objectives. Calprotectin, a protein released by neutrophils, has been used in many studies as a biomarker showing the presence of inflammation. In this study, it was aimed to investigate the relationship between serum calprotectin level and response to the treatment of idiopathic sudden sensorineural hearing loss (ISSHL). Methods. The present study is a prospective, cross-sectional historical cohort study. The study group consisted of 44 patients with ISSHL, and the control group consisted of 41 healthy volunteers without ear pathology. At the same time, patients in the study group were divided into three groups according to the response to ISSHL treatment (recovered, partially recovered, unrecovered). The relationship between the groups was statistically evaluated in terms of serum calprotectin levels. Results. The mean serum calprotectin value was 75.67±19.48 ng/mL in the study group and 50.24±29.14 ng/mL in the control group (P=0.001). Serum calprotectin value according to the severity of hearing loss in the mild, moderate and severe was 66.20±8.82, 70.35±16.77, and 91.23±19.73 ng/mL, respectively. Serum calprotectin value in the severe group was significantly higher compared to the moderate and mild groups (P=0.004, P=0.001, respectively). Serum calprotectin value according to the treatment response in the recovered, partially recovered and unrecovered groups was 63.36±11.54, 80.17±12.06, and 85.33±22.33 ng/mL, respectively. Serum calprotectin value in the recovered group was significantly lower compared to the partially recovered and unrecovered groups (P=0.002, P=0.001, respectively). Conclusion. Serum calprotectin value informs the clinician about both the severity of hearing loss and the response to treatment. Hence, serum calprotectin can be used as an important biomarker in ISSHL patients for the determination of the prognosis of disease.

참고문헌 (16)

참고문헌 신청

Stachler RJ / 2012 / Clinical practice guideline: sudden hearing loss / Otolaryngol Head Neck Surg 146(3 Suppl):S1~S35

Sano H / 2013 / Quality of life reported by patients with idiopathic sudden sensorineural hearing loss / Otol Neurotol 34(1):36~40

Kim JY / 2018 / Association of idiopathic sudden sensorineural hearing loss with affective disorders / JAMA Otolaryngol Head Neck Surg 144(7):614~621

Topuz MF / 2017 / Circulating calprotectin as a biomarker of laryngeal carcinoma / Eur Arch Otorhinolaryngol 274(6):2499~2504

Striz I / 2004 / Calprotectin : a pleiotropic molecule in acute and chronic inflammation / Physiol Res 53(3):245~253

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!